| Database ID | Agent | Target | Cancer Type | Detail |
| DB00121 | cediranib | Vascular endothelial growth factor receptor 2 | liver cancer | view |
| DB00122 | axitinib | Macrophage colonystimulating factor 1
Vascular endothelial growth factor receptor 2
Plateletderived growth factor receptor | liver cancer | view |
| DB00123 | tivantinib | Protooncogene cMet | non small cell lung cancer | view |
| DB00124 | tivantinib | Protooncogene cMet | liver cancer | view |
| DB00125 | tivozanib | VEGF2 receptor
Vascular endothelial growth factor receptor 3
Vascular endothelial growth factor receptor 1 | advanced solid tumors | view |
| DB00126 | CUDC101 | Erbb2 tyrosine kinase receptor
Epidermal growth factor receptor | advanced solid tumors | view |
| DB00127 | everolimus | Serine/threonineprotein kinase mTOR | liver cancer | view |
| DB00128 | everolimus | Serine/threonineprotein kinase mTOR | liver cancer | view |
| DB00129 | everolimus | Serine/threonineprotein kinase mTOR | liver cancer | view |
| DB00130 | everolimus | Serine/threonineprotein kinase mTOR | liver cancer | view |
| DB00131 | LY2157299 | TGFbeta receptor type I | advanced solid tumors | view |
| DB00132 | sirolimus/rapamycin | Serine/threonineprotein kinase mTOR | biliary tract, gallbladder cancer and liver cancer | view |
| DB00133 | galunisertib | TGFbeta receptor type I | advanced solid tumors | view |
| DB00134 | INC280 | Hepatocyte growth factor receptor | advanced solid tumors | view |
| DB00135 | MSC2156119J | Hepatocyte growth factor receptor | advanced solid tumors | view |